Long COVID: Skeptics Are Wrong, Researchers Say
WHRY collaborator Akiko Iwasaki, PhD, joins Fiona Lowenstein, editor of “The Long COVID Survival Guide,” to discuss patients who say they’re suffering from Long COVID for as much as two years after their acute phase of the disease. Listen to their discussion as part of "Conversations on Health Care."Source: Community Health Center
‘Prime and Spike’ Nasal Vaccine Strategy Helps Combat COVID
The new “prime” and “spike” approach may help prevent breakthrough infections of vaccinated individuals by bolstering immune response within the mucosal lining of the respiratory tract, which are the first cells attacked by COVID-19.Source: YaleNews
Herold is New Chair of International Diabetes Consortium
Kevan C. Herold, MD, C.N.H. Long Professor of Immunobiology and professor of medicine (endocrinology) at Yale School of Medicine, has been named chair of Type 1 Diabetes (T1D) TrialNet, an international consortium dedicated to finding ways to prevent, delay, and slow progression of the disease.
Immunotherapy delays type 1 diabetes in people at high risk
A drug that targets the immune system can delay the onset of type 1 diabetes in people at high risk of developing the disease, said a Yale investigator who led the National Institutes of Health-funded Diabetes TrialNet study. The research is the first to show that the progression of type 1 diabetes can be slowed by two or more years with immunotherapy.
Iwasaki Is Honored by the International Cytokine & Interferon Society
Akiko Iwasaki, PhD, Waldemar Von Zedtwitz Profesor of Immunobiology and Molecular, Cellular, and Developmental Biology; and professor of dermatology, is a 2019 recipient of the Seymour & Vivian Milstein Award for Excellence in Interferon and Cytokine Research, given by the International Cytokine & Interferon Society (ICIS).
Next frontier in study of gut bacteria: mining microbial molecules
The human gut harbors trillions of invisible microbial inhabitants, referred to as the microbiota, that collectively produce thousands of unique small molecules. The sources and biological functions of the vast majority of these molecules are unknown. Yale researchers recently applied a new technology to uncover microbiota-derived chemicals that affect human physiology, revealing a complex network of interactions with potentially broad-reaching impacts on human health.
Insulin Pump Changes Diabetes Treatment
Like many discoveries, the development of the first insulin pump was a combination of ingenuity and teamwork. In 1979, Yale doctors were conducting studies to figure out the best way to deliver insulin to children who suffer from diabetes. They discovered that giving small amounts continuously with larger doses at meals worked better than giving one large dose, because the smaller doses more closely resemble the way the pancreas produces insulin.